NATCO Pharma Limited has announced a strategic expansion through the incorporation of a new wholly owned subsidiary in Chile, named NATCO Pharma Chile SPA. The Board of Directors approved this move, earmarking a maximum investment of US$ 3,00,000 (Three Lakh USD). The subsidiary will focus on the pharmaceuticals sector, aligning with NATCO’s core business. This move is subject to standard FEMA and local regulatory approvals.
Strategic Overseas Expansion Approved
NATCO Pharma Limited has officially confirmed that its Board of Directors has approved the incorporation of a new wholly owned subsidiary located in Chile. This strategic decision was finalized during the board meeting held on February 12, 2026.
Details of the New Entity
The proposed entity will be registered as NATCO Pharma Chile SPA. The primary line of business for this new subsidiary will be pharmaceuticals, furthering the group’s international presence in this core industry. The holding company relationship is straightforward: NATCO Pharma Limited will be the direct parent, resulting in a 100% shareholding and control over the new Chilean entity.
Investment Commitment
The proposed investment to fund the incorporation and initial operations has been capped at a maximum of US$ 300,000 (Three Lakh United States Dollars). This capital will be provided as Cash consideration for the subscription of shares. The company noted that the incorporation is pending the necessary FEMA regulations and other required regulatory approvals in Chile.
Source: BSE
